These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD. Arthritis Rheum; 2011 Mar 20; 63(3):622-32. PubMed ID: 21360491 [Abstract] [Full Text] [Related]
3. Purulent pericarditis in a patient with rheumatoid arthritis treated with etanercept and methotrexate. Sweet DD, Isac G, Morrison B, Fenwick J, Dhingra V. CJEM; 2007 Jan 20; 9(1):40-2. PubMed ID: 17391602 [Abstract] [Full Text] [Related]
4. [Case of rheumatoid arthritis presenting with pulmonary tuberculosis]. Katoh K, Taniguchi H, Okouchi A, Kudo M, Kawai T. Nihon Kokyuki Gakkai Zasshi; 2004 Aug 20; 42(8):782-6. PubMed ID: 15455955 [Abstract] [Full Text] [Related]
5. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up. Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A. Int J Rheum Dis; 2012 Jun 20; 15(3):330-5. PubMed ID: 22709496 [Abstract] [Full Text] [Related]
6. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Wolfe F, Caplan L, Michaud K. Arthritis Rheum; 2006 Feb 20; 54(2):628-34. PubMed ID: 16447241 [Abstract] [Full Text] [Related]
7. [Non tuberculous anti-TNF associated opportunistic infections]. Marie I, Guglielmino E. Rev Med Interne; 2010 May 20; 31(5):353-60. PubMed ID: 20381217 [Abstract] [Full Text] [Related]
8. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S. Int J Rheum Dis; 2009 Jul 20; 12(2):118-24. PubMed ID: 20374328 [Abstract] [Full Text] [Related]
9. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG. Arthritis Rheum; 2007 Apr 20; 56(4):1125-33. PubMed ID: 17393394 [Abstract] [Full Text] [Related]
10. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis. Asahina A, Ishii N, Tohma S. J Dermatol; 2012 Feb 20; 39(2):199-201. PubMed ID: 21463364 [No Abstract] [Full Text] [Related]
12. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage. Prescrire Int; 2009 Oct 20; 18(103):198-201. PubMed ID: 19882783 [Abstract] [Full Text] [Related]
13. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed G, Calabrese L, Hooper M, Baumgartner S, Furst DE, CORRONA Investigators. Ann Rheum Dis; 2010 Sep 20; 69(9):1612-7. PubMed ID: 20448284 [Abstract] [Full Text] [Related]
14. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, Listing J, Zink A. Ann Rheum Dis; 2009 Dec 20; 68(12):1856-62. PubMed ID: 19126559 [Abstract] [Full Text] [Related]
15. Coxiella burnetii infection (Q fever) in rheumatoid arthritis patients with and without anti-TNFα therapy. Schoffelen T, Kampschreur LM, van Roeden SE, Wever PC, den Broeder AA, Nabuurs-Franssen MH, Sprong T, Joosten LA, van Riel PL, Oosterheert JJ, van Deuren M, Creemers MC. Ann Rheum Dis; 2014 Jul 20; 73(7):1436-8. PubMed ID: 24794150 [No Abstract] [Full Text] [Related]
16. Therapies for active rheumatoid arthritis after methotrexate failure. O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH, Leatherman S, Keystone E, CSP 551 RACAT Investigators. N Engl J Med; 2013 Jul 25; 369(4):307-18. PubMed ID: 23755969 [Abstract] [Full Text] [Related]
17. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? Ehlers S. J Rheumatol Suppl; 2005 Mar 25; 74():35-9. PubMed ID: 15742463 [Abstract] [Full Text] [Related]
18. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, Giardina A, Marchesoni A, Salaffi F, Ziglioli T, Lapadula G, Gruppo Italiano di Studio sulle Early Arthritides (GISEA). J Rheumatol; 2012 Jun 25; 39(6):1179-84. PubMed ID: 22467933 [Abstract] [Full Text] [Related]
19. [Pulmonary tuberculosis associated to adalimumab: a study of 3 cases]. Blanco Pérez JJ, Aranda Torres A, Pego Reigosa JM, Núñez Delgado M, Temes Montes E, Guerra Vales JL. Arch Bronconeumol; 2010 Apr 25; 46(4):203-5. PubMed ID: 19896259 [Abstract] [Full Text] [Related]
20. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Koike R, Takeuchi T, Eguchi K, Miyasaka N, Japan College of Rheumatology. Mod Rheumatol; 2007 Apr 25; 17(6):451-8. PubMed ID: 18084695 [Abstract] [Full Text] [Related] Page: [Next] [New Search]